What project PT5 buys
The Protect System Development & Demonstration (SDD) Project enhances mission performance and provides effective protection against current and emerging threats by rapidly developing and fielding modernized protection capabilities. Developmental efforts focus on advances in materials and systems engineering to enhance protective properties against a broader array of hazards, while reducing operational challenges and logistical burdens. Developmental efforts focus on advanced medical countermeasures that provide safe and effective medical defenses against biological agents (bacteria, toxins, and viruses), emerging infectious diseases, and chemical agents. Efforts included in this Project are: (1) Advanced System for Protection and Integration Reduction of Encumbrances (ASPIRE) (2) Advanced System for Protection and Integration Reduction of Encumbrances - Enhanced Biological Defense (ASPIRE-ENBD) (3) Biological Containment Isolation System - Enhanced Biological Defense (BCIS-ENBD) (4) Portable Patient Transport System - Enhanced Biological Defense (PPTS-ENBD) (5) Rapid Access to Products in Development (RAPID) (6) Shipboard Isolation System (SIS) (7) Uniform Integrated Protective Ensemble Family of Systems Gloves (UIPE FOS GLOVES) (8) Uniform Integrated Protective Ensemble Family of Systems General Purpose (UIPE FOS GP) (9) Next Generation Individual Protection (NG IP) (10) Botulinum Monoclonal Antibodies (BOT MAB) – Manufacturing/Clinical/Non Clinical (11) Vaccine Acceleration By Modular Progression - Enhanced Biological Defense (VAMP-ENBD)
- Product Development
- Support
- Test and Evaluation
- Management Services
Project PT5 funding, FY2025–FY2031
Prior years are actuals, the budget year is the request, and the outyears are the FYDP plan. Estimate types are colored and never summed into one figure. Projects carry the full five-year plan; the activities inside them stop at the budget year.
| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 40.3 |
| FY2026 | Enacted | 36.7 |
| FY2027 | Request | 25.6 |
| FY2028 | Outyear | 42.1 |
| FY2029 | Outyear | 75.5 |
| FY2030 | Outyear | 52.0 |
| FY2031 | Outyear | 62.8 |
11 accomplishments / planned programs
The R-2A exhibit — the only level of the budget that describes work that has not happened yet. Activities carry the prior, current and budget year only, no five-year plan. Coverage is partial across the corpus, so count activities, never total them.
FY2027 planned work Continue incremental development of RAPID database and initiate development of classified annexes; release RAPID database updates to stakeholders; continue storage/stability testing for select MCMs; evaluate RAPID operational capability through relevant exercises/ tabletop exercises. Continue developing regulatory documentation for MCMs.
FY2026 to FY2027 change Minor change due to routine program adjustments.
FY2026 plans — current year Continue the development/optimization of RAPID database of minimal viable product (MVP); release incremental RAPID database updates to stakeholders; evaluate RAPID operational capability through relevant exercises/mini tabletop exercises.
FY2025 accomplishments Continued the development/optimization of RAPID database to include implementation of the first version; released incremental RAPID database updates to stakeholders; evaluated RAPID operational capability through stakeholder exercises.
FY2027 planned work Continue the development and evaluation of Next Generation Individual Protection (NG IP) prototypes in support of the Joint Service Capability Needs Statement (JSCNS) by completing Phase II testing and beginning Phase III test and evaluation activities, including a Wear Trial.
FY2026 to FY2027 change The Uniform Integrated Protective Ensemble Family of Systems General Purpose (UIPE FOS GP) efforts are transitioning to NG IP starting in FY 2027.
FY2027 planned work Phase 1 testing will complete and down select to no more than 2 vendors. Exercise contract option to initiate Phase II testing.
FY2026 to FY2027 change Decrease due to the program purchasing fewer systems for Phase II testing.
FY2026 plans — current year Complete activities to achieve successful Middle Tier of Acquisition Rapid Prototyping (MTA-RP) decision in 3Q FY 2026. Achieve MTA-RP (Rapid Prototyping) decision. Award up to 3 contracts procuring up to 15 prototypes from each vendor and begin Phase I testing of prototypes.
FY2027 planned work Complete Phase I testing, conduct system down-select, and begin Phase II testing.
FY2026 to FY2027 change Increase in FY 2027 funds due to Phase I and Phase II Testing activities.
FY2026 plans — current year Complete activities to achieve successful Middle Tier of Acquisition Rapid Prototyping (MTA-RP) decision in 3Q FY 2026. Achieve MTA-RP (Rapid Prototyping) decision. Award contract and begin Phase I testing of prototypes.
FY2027 planned work Complete Phase I testing, conduct system down-select, and begin Phase II testing.
FY2026 to FY2027 change Decrease of FY 2027 funds due to the program purchasing fewer systems for Phase II testing.
FY2026 plans — current year Complete activities to achieve successful Middle Tier of Acquisition Rapid Prototyping (MTA-RP) decision in 3Q FY 2026. Achieve MTA-RP (Rapid Prototyping) decision. Award contract and begin Phase I testing of prototypes. Achieve MTA-RP (Rapid Prototyping) decision. Award contract and begin Phase I testing of prototypes.
FY2027 planned work Complete Operational Testing (OT) on General Purpose Glove (GPG). Initiate and complete Aviation Glove Heavy (AGH) and GPG analysis and documentation to support AGH Full Rate Production (FRP) in 1Q FY 2027 and GPG FRP in 2Q FY 2027.
FY2026 to FY2027 change Decrease of FY 2027 funds due to completion of Engineering and Manufacturing Development (EMD) phase and transition to Production phase.
FY2026 plans — current year Complete Aviation Gloves Heavy Developmental Testing/Operational Testing (DT/OT), initiate and complete operational demonstrations on General Purpose Glove (GPG).
FY2025 accomplishments Completed Aviation Gloves Light Developmental Testing/Operational Testing (DT/OT) and achieved Full Rate Production (FRP) and Fielding Decision (FD) for AGL in 4QFY25. Initiated Aviation Glove Heavy (AGH) DT/OT.
FY2025 accomplishments Completed all outstanding testing and awarded final prototype contract in order to facilitate the orderly shutdown.
FY2026 to FY2027 change Program/project is entering completion and all activities will be closed. Program ends in FY 2026.
FY2026 plans — current year Complete program closeout activities and archive data in support of orderly closeout.
FY2025 accomplishments Continued prototype evaluation, and testing of bio mask. Incorporated initial user feedback and evaluations into prototype. Evaluated ocular protection scalability to meet the intent of the Chemical Biological Defense Program 2022 Enhanced Biodefense and Pandemic Preparedness Narrative.
FY2026 to FY2027 change Program/project terminated in FY 2026. Program efforts will be transitioning to Next Generation Individual Protection (NG IP) starting in FY 2027.
FY2026 plans — current year Initiate Phase I and phase II test and evaluation activities for Next Generation Individual Protection (NG IP). Award contract options for materials and full prototype suits.
FY2025 accomplishments Completed all outstanding testing in order to facilitate the orderly shutdown of Engineering and Manufacturing Development (EMD) activities in order to transition program efforts to Next Generation - Individual Protection. Accelerated developmental investments for a future suit.
FY2025 accomplishments Phase 2 clinical trial and manufacturing completed, non clinical studies to be completed in 3QFY26. Program transitioning to Joint Product Lead (JPL) Enabling Biotechnologies (EB) Rapid Access Products In Development (RAPID) program by 4QFY26.
FY2025 accomplishments Progressed development and testing in safety and efficacy clinical trials of a pan-viral vaccine candidate to protect against respiratory viruses.
Named performers on project PT5
Performers named in the R-3 exhibit under this project. Share is of the project's whole FY2027 R-3 total — the same denominator the program-element split uses, so the two read on one scale and will not sum to 100% when unnamed or government work is in the mix. Budget-justification contract funding, not obligations.